Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

Francesco Pegoraro, Valerio Maniscalco, Francesco Peyronel, Pieter J. Westenend, Tadek R. Hendriksz, Rosa M. Roperto, Alessandro A. Palumbo, Elena Sieni, Paola Romagnani, Eric F. H. van Bommel, Augusto Vaglio

Blood (2020) 135 (22): 1994–1997.

https://doi.org/10.1182/blood.2019004478

Published: 2020

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Fleur Cohen-Aubart, MD PhD, Ahmed Idbaih, MD PhD, Damien Galanaud, MD PhD, Bruno Law-Ye, MD, Jean-François Emile, MD PhD, Frédéric Charlotte, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Julien Haroche

Blood (2019) 134 (Supplement_1): 4272.

https://doi.org/10.1182/blood-2019-130606

Published: 2019

Journal Articles

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Gordon Ruan, MD, Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, N. Nora Bennani, MD, Karen Rech, MD, Jason Young, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 5895.

https://doi.org/10.1182/blood-2019-124891

Published: 2019

Journal Articles

Molecular Alterations in Adult Histiocytic Neoplasms

Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, Nora N Bennani, MD, Minetta C Liu, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 2975.

https://doi.org/10.1182/blood-2019-122286

Published: 2019

Journal Articles

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, MD PhD, Harsh Patel, BS, Vaijayanthi Kandadai Raghavan, Aaron Goodman, Tamara G. Barnes, Razelle Kurzrock, MD

Blood (2019) 134 (Supplement_1): 2319.

https://doi.org/10.1182/blood-2019-126342

Published: 2019

Journal Articles

High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment

Anaïs Roeser, MD, Marine Bravetti, MD, Levi-Dan Azoulay, MD, Makoto Miyara, MD, Jean-François Emile, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Fleur Cohen-Aubart, MD PhD, Julien Haroche

Blood (2019) 134 (Supplement_1): 2324.

https://doi.org/10.1182/blood-2019-129984

Published: 2019

Journal Articles

Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations

Lucas R. Massoth, MD, Yin P. Hung, MD, PhD, Judith A. Ferry, MD, Robert P. Hasserjian, MD, Abner Louissaint, Jr., MD PhD, Meagan Montesion, PhD, Ethan S. Sokol, PhD, Dean C. Pavlick, Nikunj Shah, Natalie Danziger, Jonathan Keith Killian, MD,PhD, Eric A. Severson, MD, PhD, MMSc, Daniel Duncan, MD, Julia A. Elvin, MD, PhD, Vincent A. Miller, MD, Jeffrey S. Ross, MD, Jo-Anne Vergilio, MD, Lawrence R. Zukerberg, MD, Erik A. Williams, MD

Blood (2019) 134 (Supplement_1): 2541.

https://doi.org/10.1182/blood-2019-123729

Published: 2019

Journal Articles

PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease

Frédéric Charlotte, MD, Fleur Cohen-Aubart, MD PhD, Levi-Dan Azoulay, MD, Jean Donadieu, MD PhD, Jean-François Emile, MD PhD, Zahir Amoura, MD, Julien Haroche

Blood (2018) 132 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2018-99-114031

Published: 2018

Journal Articles

Clinical and PET Responses to Long-Term High-Dose Interferon-α Treatment Among Patients with Erdheim-Chester Disease

Xinxin Cao, Na Niu, Jian Sun, Hao Cai, Feng-dan Wang, Yi-ning Wang, Ding-rong Zhong, Ming-hui Duan, MD, Dao-bin Zhou, MD, Jian Li, MD

Blood (2018) 132 (Supplement 1): 5215.

https://doi.org/10.1182/blood-2018-99-114040

Published: 2018

Journal Articles

Acquired Hematologic Disorders of Ras-MAPK Activation

Carl E. Allen, MD PhD

Blood (2018) 132 (Supplement 1): SCI-42.

https://doi.org/10.1182/blood-2018-99-109380

Published: 2018

Journal Articles

The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease

Ran Weissman, MSc, Nir Pilar, MD, Benjamin H Durham, MD BS, Michelle Ki, BSc, Roei D Mazor, MD, Omar I Abdel-Wahab, MD, Noam Shomron, PhD, Ofer Shpilberg, MD MPH, Eli L Diamond, MD, Oshrat Rokah, PhD

Blood (2018) 132 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2018-99-112388

Published: 2018

Journal Articles

Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing

Gaurav Goyal, MBBS, Robert Vassallo, MD, Karen L Rech, MD, Jay H Ryu, MD, Caroline J Davidge-Pitts, MBBCh, W Oliver Tobin, MBBCh, PhD, Matthew J Koster, MD, Nabila Nora Bennani, MD, Mithun Vinod Shah, MD PhD, Minetta C Liu, MD, Ronald S. Go, MD

Blood (2018) 132 (Supplement 1): 1112.

https://doi.org/10.1182/blood-2018-99-113196

Published: 2018

Journal Articles

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Benjamin H Durham, MD BS, Estibaliz Lopez-Rodrigo, MD, David H Abramson, MD, Jennifer Picarsic, MD, Alessandro Pastore, Diana Mandelker, MD PhD, Michael Francis Walsh, MD, Maria E Arcila, MD, Marc Ladanyi, MD, David Solit, MD, Michael F. Berger, PhD, David M. Hyman, MD, Michelle Ki, BSc, Ira Dunkel, MD, Frederic Geissmann, MD PhD, Eli L Diamond, MD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 49.

https://doi.org/10.1182/blood-2018-99-114248

Published: 2018

Journal Articles

Clonal Hematopoiesis in Erdheim-Chester Disease

Julien Haroche, MD PhD, Stéphanie Poulain, MD PhD, Alice Marceau-Renaut, PharmD, Aline Renneville, Catherine Settegrana, Karim Maloum, Damien Roos-Weil, Florence Nguyen-Khac, MD PhD, Jean Donadieu, MD, Jean-François Emile, MD PhD, Zahir Amoura, Fleur Cohen-Aubart, MD PhD

Blood (2017) 130 (Supplement 1): 3788.

https://doi.org/10.1182/blood.V130.Suppl_1.3788.3788

Published: 2017

Journal Articles

Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders

Eli L Diamond, MD, Benjamin H Durham, MD BS, Ahmet Dogan, MD PhD, David M. Hyman, MD, Raajit K. Rampal, MD PhD, Gary Ulaner, MD, Lynn Brody, MD, Omar Abdel-Wahab, MD

Blood (2017) 130 (Supplement 1): 257.

https://doi.org/10.1182/blood.V130.Suppl_1.257.257

Published: 2017

Journal Articles

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

Fleur Cohen Aubart, Jean-François Emile, Fabrice Carrat, Frédéric Charlotte, Neila Benameur, Jean Donadieu, Philippe Maksud, Ahmed Idbaih, Stéphane Barete, Khê Hoang-Xuan, Zahir Amoura, Julien Haroche

Blood (2017) 130 (11): 1377–1380.

https://doi.org/10.1182/blood-2017-03-771873

Published: 2017

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease: the “targeted” revolution

Augusto Vaglio, Eli L. Diamond

Blood (2017) 130 (11): 1282–1284.

https://doi.org/10.1182/blood-2017-07-795054

Published: 2017

Journal Articles

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults

Paul Milne, Venetia Bigley, Chris M. Bacon, Antoine Néel, Naomi McGovern, Simon Bomken, Muzlifah Haniffa, Eli L. Diamond, Benjamin H. Durham, Johannes Visser, David Hunt, Harsha Gunawardena, Mac Macheta, Kenneth L. McClain, Carl Allen, Omar Abdel-Wahab, Matthew Collin

Blood (2017) 130 (2): 167–175.

https://doi.org/10.1182/blood-2016-12-757823

Published: 2017

Includes: Supplemental data

NARROW

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Erdheim-Chester disease

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Molecular Alterations in Adult Histiocytic Neoplasms

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment

Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations

PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease

Clinical and PET Responses to Long-Term High-Dose Interferon-α Treatment Among Patients with Erdheim-Chester Disease

Acquired Hematologic Disorders of Ras-MAPK Activation

The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease

Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Clonal Hematopoiesis in Erdheim-Chester Disease

Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

Erdheim-Chester disease: the “targeted” revolution

Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only